Teva fails to get US antitrust class action over alleged asthma inhaler scheme thrown out
By Alex Wilts ( May 8, 2024, 00:25 GMT | Insight) -- Teva Pharmaceuticals was unable to convince a US judge to entirely dismiss antitrust allegations that the company conspired to delay generic competition to its prescription asthma treatment products QVAR and QVAR Redihaler.Teva Pharmaceuticals was unable to convince a US judge to entirely dismiss antitrust allegations that the company conspired to delay generic competition to its prescription asthma treatment products QVAR and QVAR Redihaler....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.